• 1. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 2. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 3. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 4. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 5. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines Imidazopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines

Ethyl 3-bromo-5-methylimidazo[1,2-a]pyridine-2-carboxylate (CAS No. 1123167-64-5): A Key Intermediate in Modern Pharmaceutical Research

Ethyl 3-bromo-5-methylimidazo[1,2-a]pyridine-2-carboxylate (CAS No. 1123167-64-5) is a highly valuable intermediate in the realm of pharmaceutical chemistry, playing a pivotal role in the synthesis of various bioactive molecules. This compound, characterized by its imidazopyridine core structure, has garnered significant attention due to its versatility and utility in drug discovery programs.

The molecular framework of Ethyl 3-bromo-5-methylimidazo[1,2-a]pyridine-2-carboxylate consists of a fused imidazole and pyridine ring system, which is further functionalized with a bromo substituent at the 3-position and a methyl group at the 5-position. The presence of these functional groups makes it an attractive scaffold for medicinal chemists seeking to develop novel therapeutic agents. The ester moiety at the 2-position provides a handle for further chemical modifications, enabling the synthesis of more complex derivatives.

In recent years, there has been a surge in research focused on imidazopyridine derivatives due to their demonstrated pharmacological properties. These compounds have shown promise in various therapeutic areas, including oncology, inflammation, and central nervous system disorders. The bromo group in Ethyl 3-bromo-5-methylimidazo[1,2-a]pyridine-2-carboxylate is particularly noteworthy, as it serves as a versatile handle for cross-coupling reactions such as Suzuki-Miyaura and Buchwald-Hartwig couplings. These reactions are fundamental in constructing more intricate molecular architectures, thereby expanding the pharmacophoric space for drug development.

One of the most compelling aspects of Ethyl 3-bromo-5-methylimidazo[1,2-a]pyridine-2-carboxylate is its utility in generating libraries of compounds for high-throughput screening (HTS). The structural diversity introduced by varying the substituents on the imidazopyridine core allows for the exploration of multiple biological targets simultaneously. This approach has been successfully employed in academic and industrial settings to identify lead compounds with high affinity and selectivity.

The synthesis of Ethyl 3-bromo-5-methylimidazo[1,2-a]pyridine-2-carboxylate typically involves multi-step organic transformations starting from readily available precursors. The bromination and methylation steps are critical in establishing the desired substitution pattern on the imidazopyridine ring system. Advanced synthetic techniques, such as palladium-catalyzed cross-coupling reactions, have been optimized to achieve high yields and purity levels, ensuring that the intermediate is suitable for subsequent pharmaceutical applications.

In the context of drug discovery, Ethyl 3-bromo-5-methylimidazo[1,2-a]pyridine-2-carboxylate has been utilized in the development of kinase inhibitors, which are widely used to treat various types of cancer. The imidazopyridine scaffold is known to interact effectively with ATP-binding pockets of kinases, thereby inhibiting their activity. By incorporating different substituents into this core structure, researchers can fine-tune the binding properties and improve the pharmacokinetic profiles of these inhibitors.

Furthermore, the ester group in Ethyl 3-bromo-5-methylimidazo[1,2-a]pyridine-2-carboxylate can be hydrolyzed to yield a carboxylic acid derivative, which can then be further functionalized through amide bond formation. This transformation opens up avenues for developing peptidomimetics and other bioconjugates that mimic natural peptides but with improved stability and bioavailability.

The growing interest in fragment-based drug design has also highlighted the importance of intermediates like Ethyl 3-bromo-5-methylimidazo[1,2-a]pyridine-2-carboxylate. Fragment-based approaches rely on identifying small molecular fragments that bind to target proteins with moderate affinity. These fragments can then be linked together or modified to produce lead compounds with higher potency. The structural features of this compound make it an excellent candidate for such strategies.

Recent studies have demonstrated the efficacy of imidazopyridine derivatives in modulating inflammatory pathways. For instance, certain analogs have shown anti-inflammatory activity by inhibiting key enzymes involved in cytokine production. This has sparked further investigation into the potential therapeutic applications of these compounds in conditions such as rheumatoid arthritis and inflammatory bowel disease.

The role of computational chemistry in optimizing derivatives of Ethyl 3-bromo-5-methylimidazo[1,2-a]pyridine-2-carboxylate cannot be overstated. Molecular modeling techniques have been employed to predict binding affinities and optimize pharmacokinetic properties before experimental synthesis is undertaken. This approach not only saves time but also reduces costs associated with trial-and-error experimentation.

In conclusion, Ethyl 3-bromo-5-methylimidazo[1,2-a]pyridine-2-carboxylate (CAS No. 1123167-64-5) represents a cornerstone intermediate in modern pharmaceutical research. Its unique structural features and reactivity make it an indispensable tool for medicinal chemists striving to develop novel therapeutics across multiple disease areas. As research continues to uncover new applications for this compound and its derivatives, its importance in drug discovery is set to grow even further.

• 143982-54-1(Ethyl 3-bromoimidazo[1,2-A]pyridine-2-carboxylate)
• 429690-68-6(IMIDAZO[1,2-A]PYRIDINE-5-CARBOXYLIC ACID, 3-BROMO-2-FORMYL-, ETHYL ESTER)
• 429690-47-1(Imidazo[1,2-a]pyridine-2,5-dicarboxylic acid, 3-bromo-, diethyl ester)
• 1332589-38-4(3-Bromo-8-methyl-imidazo1,2-apyridine-2-carboxylic acid ethyl ester hydrobromide)
• 1332588-44-9(3-Bromo-7-methyl-imidazo1,2-apyridine-2-carboxylic acid ethyl ester hydrobromide)
• 1119448-99-5(ethyl 3,6-dibromoimidazo[1,2-a]pyridine-2-carboxylate)
• 113508-58-0(Imidazo[1,2-a]quinoline-2-carboxylic acid, 1-bromo-, ethyl ester)
• 861208-16-4(Ethyl 3-Bromo-6-chloroimidazo1,2-apyridine-2-carboxylate)
• 429690-42-6(Ethyl 3-bromoimidazo[1,2-a]pyridine-5-carboxylate)
• 429690-55-1(Imidazo[1,2-a]pyridine-2-carboxylic acid, 3-bromo-5-formyl-, ethyl ester)